Polyepitope Vaccine Construction with Optimized Spacer Design

Creative Biolabs offers specialized preclinical services in polyepitope vaccine design and development, an approach that links consecutive cytotoxic T lymphocyte (CTL) epitopes into a single polypeptide construct to achieve broad HLA coverage and multi-pathogen targeting. Unlike full-length antigen vaccines, polyepitope constructs eliminate risks associated with the oncogenicity or toxicity of native proteins while maintaining the ability to prime specific CD8+ and CD4+ T cell responses across diverse HLA haplotypes. Our team provides end-to-end support, from epitope selection and construct optimization to delivery vehicle engineering and in vitro/in vivo immunogenicity validation, enabling researchers to advance polyepitope vaccine candidates toward preclinical proof-of-concept with confidence.

How Polyepitope Constructs Broaden T-Cell Immunity

One Construct, Many Epitopes

A polyepitope vaccine is an engineered polypeptide in which multiple defined CTL epitopes are linked end-to-end, often without the need for native flanking sequences. This design enables a single immunogen to present epitopes restricted by multiple HLA class I and class II molecules, overcoming the HLA diversity barrier that limits single-epitope vaccines. Because the construct contains only the minimal immunogenic sequences, it avoids potential toxicity or autoimmune reactions associated with full-length tumor antigens.

Why Polyepitope over Full-Length Antigens?
Full-length tumor-associated antigens can carry oncogenic risk or exhibit poor immunogenicity due to self-tolerance. Polyepitope constructs bypass these limitations by including only well-characterized, immunodominant epitopes, allowing precise control over the breadth and specificity of the T cell response.

Core Preclinical Challenges We Address:
Eliminating junctional neo-epitopes in multi-epitope strings through optimized epitope ordering.
Achieving broad HLA population coverage exceeding 90% with curated epitope panels.
Enhancing proteasomal processing via ubiquitin fusion and spacer design optimization.
Validating epitope-specific T cell responses in vitro and in vivo after construct delivery.

Polyepitope Vaccines vs. Full-Length Antigen and Single-Epitope Approaches

Key Comparison	Full-Length Antigen / Single-Epitope Vaccines	Polyepitope Vaccines
HLA Population Coverage	Limited to a few HLA alleles (single epitope) or unpredictable (full antigen).	Deliberate multi-HLA epitope selection for >90% coverage.
Oncogenic / Toxicity Risk	Full-length oncoproteins may retain transforming activity.	Minimal epitopes only; no oncogenic or toxic domains.
Immune Escape Prevention	Single epitope: vulnerable to antigen loss or mutation.	Simultaneous multi-epitope targeting reduces escape risk.
Construct Design Flexibility	Fixed by native protein sequence; limited engineerability.	Fully modular: epitopes, linkers, adjuvants, and tags are tunable.

End-to-End Polyepitope Vaccine Development Services

Our preclinical polyepitope vaccine services are organized into modular, customizable packages. Whether you need a single epitope validated or a full polyepitope construct delivered and tested in vivo, each module can be adapted to your specific pathogen target, HLA requirements, and delivery platform.

Strategy

Epitope Discovery & HLA Coverage Planning

Systematic identification of immunodominant CTL epitopes with broad population coverage.

Epitope Mining: Database-driven screening of IEDB and literature for validated CTL epitopes.
HLA Coverage Analysis: Computational modeling of allele frequencies for target populations (global or regional).
Conservation Assessment: Sequence conservation analysis across viral strains or tumor subtypes.
Immunogenicity Ranking: Prioritization based on binding affinity, antigenicity, and published T cell response data.

Design

Polyepitope Construct Design & Optimization

Engineering the polyepitope string for maximal antigen processing and minimal junctional artifacts.

Epitope Ordering: Junctional neo-epitope minimization using dedicated optimization algorithms.
Spacer Engineering: AAY or native flanking sequence insertion for efficient proteasomal liberation.
Ubiquitin Fusion: N-terminal ubiquitin tagging (G76V mutant) to accelerate proteasomal degradation.
In Silico Validation: Molecular docking of epitope-HLA interactions to confirm predicted binding.

Production

Gene Synthesis & Delivery Vehicle Assembly

Construct production and packaging into the optimal delivery platform for your research question.

Gene Synthesis: Codon-optimized polyepitope gene synthesis for the chosen expression system.
Viral Vectors: Recombinant vaccinia virus, modified vaccinia Ankara (MVA), or adenoviral vector construction.
DNA Plasmids: Preclinical-grade plasmid preparation for DNA vaccination studies.
Protein Formulation: Polyepitope protein expression and formulation with ISCOM adjuvants.

Engineering

Adjuvant & Formulation Strategy

Enhancing vaccine potency through rational adjuvant pairing and delivery optimization.

Adjuvant Selection: TLR agonists, CpG, or ISCOM formulation tailored to the delivery vehicle.
Lymph Node Targeting: Amphiphile-adjuvant conjugation for efficient lymph node delivery.
Combination Design: Co-formulation with immune checkpoint inhibitors for synergy studies.
Stability Testing: Formulation integrity and functional assay under storage conditions.

Potency

Comprehensive Immunogenicity Evaluation

Rigorous multi-level assessment of polyepitope vaccine-induced T cell responses.

In Vitro Assays: PBMC stimulation, IFN-γ ELISpot, and intracellular cytokine staining.
Epitope Mapping: Individual epitope-specific T cell response profiling across the polyepitope string.
In Vivo POC: HLA-transgenic mouse immunization and tumor challenge models.
Immune Profiling: TCR repertoire sequencing and polyfunctionality analysis.

Support

QC & Preclinical Data Package

Comprehensive quality characterization and data reporting for translational research.

Construct Verification: Sequence confirmation and expression validation by Western blot and mass spectrometry.
Potency Assurance: Functional T cell activation assays as release criteria for cell and gene products.
Safety Screening: Biodistribution and toxicity evaluation in relevant animal models.
Regulatory Documentation: Pre-IND data package compilation and CMC documentation support.

Optimized Polyepitope Vaccine Development Workflow

Integrated polyepitope vaccine development workflow

Phase 1 — Epitope Identification & HLA Coverage Mapping

We begin with comprehensive database mining (IEDB, published literature) and computational epitope prediction to identify candidate CTL epitopes from your target antigen(s). HLA binding affinity prediction and allele frequency analysis ensure that the selected epitope panel achieves maximal population coverage, typically exceeding 90% for global populations.

Phase 2 — Polyepitope String Engineering & Optimization

Selected epitopes are assembled into a single open reading frame. Our optimization pipeline uses junctional neo-epitope minimization algorithms, spacer design (AAY or native flanking sequences), and N-terminal ubiquitin fusion to maximize proteasomal processing and MHC class I presentation. Long epitope formats (≥20-mers with native flanking sequences) are preferred to ensure natural epitope liberation.

Phase 3 — Gene Synthesis & Delivery Vehicle Construction

The optimized polyepitope gene is synthesized with codon optimization for the chosen expression system. We construct the appropriate delivery vehicle—viral vectors (vaccinia virus, MVA, adenovirus), DNA plasmids, or protein expression systems—based on your experimental requirements and target application.

Phase 4 — Adjuvant Pairing & Formulation Optimization

We screen and select the optimal adjuvant and formulation strategy for the chosen delivery platform. Options include TLR agonists, CpG-based lymph node targeting amphiphile conjugates, and ISCOM-based protein formulations. Combination strategies with checkpoint blockade agents can be designed to evaluate synergistic antitumor effects.

Phase 5 — Comprehensive Immunogenicity & Efficacy Validation

Final vaccine candidates undergo rigorous in vitro testing (PBMC stimulation, ELISpot, intracellular cytokine staining for polyfunctionality) and in vivo evaluation in HLA-transgenic mouse models. Epitope-by-epitope T cell response mapping confirms that each component of the polyepitope string is immunogenic and contributes to the overall protective response.

Enabling Technologies for Polyepitope Vaccine Engineering

Junctional Neo-Epitope Minimization

Dedicated algorithms (e.g., pVACvector-based optimization) evaluate all possible epitope orderings to eliminate junctional sequences that could create unintended immunogenic neo-epitopes, ensuring the construct elicits only the intended immune responses.

Ubiquitin-Fused Proteasomal Targeting

N-terminal mutant ubiquitin (G76V) fusion directs the polyepitope protein into the ubiquitin-proteasome pathway, accelerating degradation and enhancing MHC class I peptide loading, resulting in stronger CD8+ T cell priming compared to untagged constructs.

Multi-Vector Delivery Platform

A versatile suite of delivery vehicles—recombinant vaccinia virus, MVA, adenoviral vectors, DNA plasmids, and ISCOM-formulated protein—enables rapid adaptation to the delivery strategy best suited for each target disease and preclinical model.

Why Choose Creative Biolabs?

Deep Expertise in Polyepitope Design

Our scientists have years of experience in multi-epitope construct engineering, from epitope selection to junctional optimization and delivery vehicle matching.

Broad HLA Coverage Analysis

We perform comprehensive HLA population coverage modeling to ensure your polyepitope construct targets the widest possible patient population across global or regional demographics.

Flexible Delivery Options

From viral vectors to DNA plasmids and ISCOM-formulated proteins, we offer multiple delivery platforms to match your specific research question and preclinical model requirements.

End-to-End Preclinical Integration

Our integrated workflow covers everything from epitope discovery to in vivo proof-of-concept, providing a seamless path from design to validated immunogenicity data.

Research Insight: Recombinant MVA Polyepitope Vaccine Design and Preclinical Evaluation

Key Preclinical Findings from our Recombinant MVA Polyepitope Study

Developing universal influenza vaccines capable of inducing broadly protective cellular immune responses is a vital global objective. Recent preclinical research successfully engineered and evaluated an artificial poly-epitope immunogen utilizing the Modified Vaccinia virus Ankara (MVA) platform, delivering promising cross-reactive T cell responses in vitro and in vivo.

Highly Conserved Epitope Selection & 99.5% HLA Population Coverage: The study selected twenty highly conserved influenza A virus (IAV) CD8+ T cell epitopes from internal proteins (NP, M1, PB1, PB2, PA) with over 50% conservation across human, swine, and avian strains. This panels' HLA restriction targets an estimated 99.5% of the global human population, assuring high versatility.
Ubiquitin Fusion & Optimized AAY Spacers Enhance Antigen Processing: To optimize proteasomal targeting, the construct was fused with N-terminal mutant ubiquitin (G76V), while individual epitopes were separated using AAY spacer sequences. Verification confirmed that human CTL lines successfully recognize and liberate individual epitopes regardless of their location (positions 4, 5, 10, or 14) in the poly-epitope string.
Robust In Vitro Human Reactivation & In Vivo Immunogenicity: Recombinant MVA-delivered poly-epitope vaccine (rMVA-PE) successfully reactivated and expanded memory CD8+ T cell responses in healthy HLA-typed human PBMCs, matching or exceeding responses induced by natural viral infection. Intramuscular immunization of humanized HLA-A2.1-/HLA-DR1-transgenic mice prompted highly robust antigen-specific CD8+ T cell responses in vivo.

<em>In vitro</em> immunogenicity of recombinant rMVA-PE.

Fig.1 In vitro immunogenicity analysis of rMVA-PE.^{1, 2}

FAQs Regarding Polyepitope Vaccine Development

A polyepitope vaccine encodes multiple CTL epitopes as a single continuous polypeptide within one gene or protein, ensuring coordinated expression and processing. A peptide cocktail is a mixture of separate synthetic peptides. The polyepitope approach simplifies manufacturing and delivery (especially for viral or DNA vectors) and ensures that all epitopes are delivered to the same antigen-presenting cell simultaneously.

We use dedicated optimization algorithms to evaluate all possible epitope orderings within the polyepitope string and select the arrangement that minimizes the creation of unintended junctional sequences. Additionally, we can insert defined spacer sequences (such as AAY linkers) between epitopes to ensure proper proteasomal cleavage at the intended sites.

We provide a full range of delivery platforms for preclinical studies, including recombinant vaccinia virus (VV), modified vaccinia Ankara (MVA), adenoviral vectors, DNA plasmids, and protein-based formulations with ISCOM adjuvants. The choice depends on the target disease, desired immune kinetics, and experimental model.

Yes. Our polyepitope platform is applicable to both oncology (e.g., EBV-associated malignancies, melanoma, breast and cervical cancer) and infectious disease (e.g., HIV, HBV, HCV, malaria, influenza) targets. We tailor epitope selection and construct design to the specific immunobiology and HLA restriction patterns of each indication.

We utilize HLA-transgenic mouse models to evaluate human-restricted T cell responses, syngeneic tumor models for cancer vaccine efficacy, and humanized mouse models for evaluating human-specific immune interactions. These models allow us to assess epitope-specific T cell activation, tumor growth inhibition, and immune memory formation under preclinical conditions.